Efficacy and safety of histamine H4 receptor antagonist ZPL-3893787 in atopic dermatitis

ZPL-3893787, a selective H4 receptor antagonist, has a clinically significant anti-inflammatory effect in moderate to severe AD in humans upon oral administration over a period of 8 weeks. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2z2uoSH